Olema Pharmaceuticals (OLMA) IPO Opens 137% Higher

Today's IPO for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) opened for trading at $45 after pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share.

In addition, Olema Oncology has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC are acting as active joint book-running managers for the offering. Canaccord Genuity LLC is also acting as a book-running manager.

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

You May Also Be Interested In

• SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
• Araghchi Says No Tangible Progress Made In US Talks - Tasnim
• Genco Shipping urges shareholders to reject Diana's $24.80 takeover bid